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Molecular tumour boards and molecular diagnostics for
patients with cancer in the Netherlands: experiences,
challenges, and aspirations
Annelieke E. C. A. B. Willemsen 1, Sarah Krausz2, Marjolijn J. L. Ligtenberg3,4, Katrien Grünberg3, Harry J. M. Groen5, Emile E. Voest6,
Edwin P. J. G. Cuppen7,8, Hanneke W. M. van Laarhoven2 and Carla M. L. van Herpen1
Advances in molecular tumour diagnostics and the number of targeted therapies increase rapidly. Molecular tumour boards (MTBs)
are designated to interpret these data and provide clinical recommendations. Not all patients with cancer have access to advice of
an MTB. We aimed to determine the current status, opportunities, and challenges of the organisation of MTBs in the Netherlands.
We interviewed several stakeholders about their experiences with an MTB, using template analysis. Most clinicians and patient
representatives underscore the significance of an MTB, because it can stimulate rational treatment options, enrolment in clinical
trials, and interdisciplinary knowledge transfer. Health insurance companies and financial managers are concerned about increasing
costs. Registries to assess the clinical benefit of MTBs, guidelines on quality control, financial agreements, and logistical resources
are lacking. The national organisation of MTBs and a registry of molecular and clinical data are important issues to address.
British Journal of Cancer (2019) 121:34–36; https://doi.org/10.1038/s41416-019-0489-3
BACKGROUND
Numerous new possibilities for precision medicine for patients
with cancer have arisen. To aid medical specialists in the highly
complex field of molecular biology and clinical care, molecular
tumour boards (MTBs) discuss the clinical relevance of genetic
aberrations with detailed genomic explanation and treatment
options. However, a recent survey shows that the advice of an
MTB is not accessible for all patients in the Netherlands and that
MTBs vary greatly in composition, tasks, tools, and workflow.1
Here, we determine the opportunities and challenges of the
organisation of MTBs in the Netherlands, from the perspectives of
different stakeholders, addressing the following questions: What is
the added value of an MTB? What is needed for its optimal
organisation and functioning? Which financial and logistical
resources are required?
METHODS
We interviewed different stakeholders in the Netherlands about
their experiences with an MTB, using a qualitative approach,
applying template analysis (supplementary Table 1). We included
health care professionals (medical oncologists, pulmonologists,
pathologists, molecular biologists, a clinical geneticist, and a
surgeon), and financial managers from hospitals with and without
MTB experience, medical oncologists in training, representatives
from a national cancer patient federation and from health
insurance companies. All respondents provided consent. A
description of data collection and data analysis is provided in
the supplementary material.
RESULTS
Demographic data of the respondents are summarised in
supplementary Table 2.
The significance of an MTB for patients and health care
professionals
Most health care professionals acknowledge the value of an MTB.
Four points of significance are mentioned. (1) Improvement of
patients’ outcomes by providing a multidisciplinary tailored-based
treatment advice. (2) Continuous interdisciplinary knowledge
transfer. (3) Cost-saving by predictive diagnostics preventing
ineffective therapy. (4) Facilitation of scientific output. The patient
federation encourages early referral to an MTB, as this can provide
personalised (extra) treatment options and improve enrolment in
clinical trials.
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Some medical oncologists are more sceptical about the current
significance of an MTB. (1) Most of their patients are discussed
with late stage disease, which can limit treatment possibilities. (2)
In contrast to many lung tumours, treatment options for other
solid tumours are more limited. (3) Many current medical
oncologists in training have not attended an MTB yet and do
not have a clear vision of the potential of an MTB. (4) Appropriate
palliative care can be delayed while waiting for an MTB advice. (5)
Most clinicians from non-MTB centres and medical oncologists in
training experience off-label prescription based on an actionable
tumour mutation as an undesirable situation. However, others
regard an MTB as a suitable forum to centralise and regulate off-
label prescriptions and the patient federation experiences off-label
prescription as an act of bravery of their treating physician.
The organisation and regulation of an MTB within local, regional
and national networks
Interdisciplinary collaboration is regarded as crucial and participa-
tion of a clinical scientist in molecular pathology is considered
indispensable. In many MTBs, the treating clinician of the patient
who is discussed is absent and relevant clinical information can be
insufficient. Some MTB-centres favour more regional collaboration
in order to increase the patient number of their MTB, while other
MTB-centres with extensive regional collaboration do not have
time for further expansion.
For the future of MTBs, some respondents propose to maintain
tumour non-selective MTBs in every specialised cancer centre and
design only one central MTB in the Netherlands for high-complex
cases. Alternatively, molecular expertise may be integrated more
within the existing tumour-specific oncology boards.
All respondents agree that evaluating the quality of an MTB is
crucial to gain maximal clinical benefit. The following items
warrant regulation and evaluation: (1) the goals of an MTB,
including which patients will be referred, (2) the composition of an
MTB, (3) registration of clinical outcomes, (4) type, quality, and
validation of molecular diagnostic procedures used.
Financial and logistical resources
Financial managers in the hospitals and representatives of health
insurance companies are concerned about increasing costs of
diagnostics and medication and stress the importance of evidence
for the benefits of MTBs. Respondents did not express need for
financial compensation for the time spent on the MTB. In community
hospitals prescription of medication off-label often is not possible
due to financial constraints. Health insurance companies are willing
to reimburse (part of) the costs of molecular diagnostics and
treatment, provided that certain conditions are satisfied: (1) criteria
for referral to an MTB, (2) insight in the clinical outcomes, and (3)
adherence to diagnostic quality demands and the composition of
the MTB. Furthermore, in their opinion, pharmaceutical companies
should contribute to reimbursement, as they benefit from an
increase in the prescription of therapeutic agents. Ultimately,
decisions on finances should be made on a national political level.
Logistical support is required for coordination of the MTB,
facilities, and reports. A simple and widely accessible registration
procedure is important. Most respondents believe an MTB report
should have a description of the molecular method, a conclusion
of the data with a treatment advice, and reference to supporting
scientific literature. Some physicians from non-MTB centres prefer
to attend the MTB to discuss their patient through teleconsulting,
while others prefer referral of the patient. Clinicians feel the urge
to discuss possible genetic unsolicited findings prior to the
application of molecular diagnostics but differ in preferences on
the details of this procedure.
The most important points of tension as described are
summarised in Table 1.
DISCUSSION
Most clinicians value the MTB, primarily for the possible extra
treatment options it provides for their patients. To improve MTBs,
first, an easily accessible national or international registry is needed
that collects molecular, treatment and follow-up data. Second,
guidelines are needed concerning the molecular diagnostic
methods, the provided clinical information, and the composition
and organisation of the MTB. Third, financial arrangements for off-
label drugs are a prerequisite to enable financial sustainability.
Finally, regional collaboration is crucial in order to assure accessibility
to an MTB for every eligible cancer patient. The large variety we
observed in MTBs is in agreement with other studies.1,2 Several
Table 1. Points of tension
Points of tension
I. Significance of MTB for patients, health care professionals, and stakeholders
a. Early versus late referral to MTB
b. Broad sequencing versus unsolicited genetic findings
c. Clinical benefit for patients versus concern about expenses of diagnostics
d. MTB is indispensable versus currently only limited clinical significance
e. Hope versus disappointment about MTB advice
f. Off-label use versus evidence-based medicine
II. The organisation and regulation of an MTB
a. differences in main focus of MTB: lung oncology versus medical oncology versus research focus
b. stronger regional collaboration versus scarcity of time to participate
c. importance of evaluating efficacy of an MTB versus lack of time and resources to perform evaluation
III. Financial and logistical resources
a. enthusiasm about technological advances versus concern about increasing costs
b. reimbursement of the molecular test only versus including innovation costs in reimbursement
c. logistical support for MTB needed versus concern about increasing costs
d. experts prefer presence of referring clinician versus insufficient time of clinicians to attend MTB
e. health insurance companies might reimburse if outcomes are good and quality control is arranged versus currently no collection of outcomes
and no quality requirements
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studies support evidence for the benefits of precision medicine.3–7
The first randomised study, the SHIVA trial, comparing precision
medicine versus conventional therapy, was negative, although this
study has considerable limitations. In the Netherlands, the DRUP
study (NCT02925234), and in the United States the TAPUR study
(NCT0269353), examine the efficacy of targeted agents based on
specific mutations and correlate treatment outcome with data on
whole gene sequencing. Furthermore, experiences with MTBs have
been described by several other centres.8–12 Our study included five
out of seven MTBs in the Netherlands; it would be of interest to
extend this research to other countries. We included representatives
of the patient federation. Yet, we acknowledge the difference in
education concerning current developments in health care com-
pared to many other patients.
In conclusion, a well-designed MTB contributes to more extensive
personalised treatment options for patients, and furthermore, guides
clinicians in their decision-making based on ongoing biotechnolo-
gical advances. For financial reimbursement of MTB-guided care by
insurance companies and governmental organisations, the imple-
mentation of quality guidelines and evidence of the clinical benefit
of MTB-guided treatment are crucial.
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